Infection Diagnosis and Management in Lung Transplant Recipients

Rationale and Clinical Context

The European Respiratory Society suggests that six months post-transplant represents a critical window for opportunistic infections in lung transplant recipients, when immunosuppression remains substantial but prophylactic antimicrobial coverage may be waning 1, 2
The International Society for Heart and Lung Transplantation recommends considering Aspergillus colonization or fungal pneumonitis as a risk factor for complications in lung transplant recipients 1, 2, 4
The American Thoracic Society notes that Aspergillus species are the most common fungal pathogens causing mass-like lesions in lung transplant recipients at this timepoint 1, 2, 3

The European Respiratory Society recommends high-resolution CT chest with contrast to characterize the lesion and assess for additional abnormalities 5, 6, 1
The American College of Chest Physicians suggests bronchoscopy with bronchoalveolar lavage (BAL) targeting the affected area for bacterial cultures, fungal cultures and galactomannan, viral studies, and cytology 5, 6, 1, 2, 3
The Infectious Diseases Society of America recommends serum galactomannan and beta-D-glucan for fungal infection screening 1

The International Society for Heart and Lung Transplantation advises that surveillance bronchoscopy is routinely offered to detect occult infections in asymptomatic lung transplant recipients 5, 6, 1, 2, 3
The American Thoracic Society suggests that for confirmed allograft infection, aggressive measures to control and eradicate infection are mandatory 5, 6, 1, 4, 2, 3
The European Respiratory Society recommends considering that infection and rejection can coexist in the allograft 5, 6, 1, 2